{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:15:46Z","timestamp":1772165746219,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Please see section in manuscript"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Malignant pleural mesothelioma (MPM) is traditionally characterized by local destructive spread of the pleura and surrounding tissues. Patient outcomes in MPM with distant metastatic dissemination are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, we reviewed a cohort of 164 MPM patients referred to a Phase I trials unit, aiming to describe identified metastatic sites, and correlate with clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      67% of patients were diagnosed with distant metastatic disease with a high incidence of bone (19%), visceral (14%), contralateral lung (35%) and peritoneal metastases (22%). Peritoneal metastases were more likely in epithelioid versus biphasic\/ sarcomatoid MPM (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.015). Overall survival was 23.8\u2009months with no statistical difference in survival between those with distant metastases and those without.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This report highlights the frequency of distant metastases and encourages further radiological investigations in the presence of symptoms. In particular, given the relatively high incidence of bone metastases, bone imaging should be considered in advanced MPM clinical workflow and trial protocols. The presence of distant metastases does not appear to have prognostic implications under existing treatment paradigms. This cohort of MPM patients gives an indication of patterns of metastatic spread that are likely to become prevalent as prognosis improves with emerging treatment paradigms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07662-y","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T06:23:52Z","timestamp":1607495032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease"],"prefix":"10.1186","volume":"20","author":[{"given":"Dearbhaile Catherine","family":"Collins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghav","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Constantinidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dolling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy Anthony","family":"Yap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udai","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann Sebastian","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juanita Suzanne","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Tunariu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9339-7101","authenticated-orcid":false,"given":"Anna","family":"Minchom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"issue":"1","key":"7662_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0305-7372(77)80016-9","volume":"4","author":"SS Legha","year":"1977","unstructured":"Legha SS, Muggia FM. Therapeutic approaches in malignant mesothelioma. Cancer Treat Rev. 1977;4(1):13\u201323.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"7662_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1056\/NEJM198007243030407","volume":"303","author":"KH Antman","year":"1980","unstructured":"Antman KH. Current concepts: malignant mesothelioma. NEJM. 1980;303(4):200\u20132.","journal-title":"NEJM"},{"issue":"4","key":"7662_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/0305-7372(88)90023-0","volume":"15","author":"G Falkson","year":"1988","unstructured":"Falkson G, Alberts AS, Falkson HC. Malignant pleural mesothelioma treatment: the current state of the art. Cancer Treat Rev. 1988;15(4):231\u201342.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"7662_CR4","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1378\/chest.11-3204","volume":"142","author":"RS Finn","year":"2012","unstructured":"Finn RS, Brims FJH, Gandhi A, Olsen N, Musk AW, Maskell NA, et al. Postmortem findings of malignant pleural mesothelioma: a two-center study of 318 patients. Chest. 2012;142(5):1267\u201373.","journal-title":"Chest"},{"issue":"7","key":"7662_CR5","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1513\/AnnalsATS.201404-165BC","volume":"11","author":"AC Miller","year":"2014","unstructured":"Miller AC, Miettinen M, Schrump DS, Hassan R. Malignant mesothelioma and central nervous system metastases. Report of two cases, pooled analysis, and systematic review. Ann Am Thorac Soc. 2014;11(7):1075\u201381.","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"7662_CR6","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejrad.2007.08.010","volume":"64","author":"M Yamamuro","year":"2007","unstructured":"Yamamuro M, Gerbaudo VH, Gill RR, Jacobson FL, Sugarbaker DJ, Hatabu H. Morphologic and functional imaging of malignant pleural mesothelioma. Eur J Radiol. 2007;64(3):356\u201366.","journal-title":"Eur J Radiol"},{"issue":"Suppl 2","key":"7662_CR7","doi-asserted-by":"publisher","first-page":"S304","DOI":"10.21037\/jtd.2017.10.19","volume":"10","author":"M Cinausero","year":"2018","unstructured":"Cinausero M, Rihawi K, Sperandi F, Melotti B, Ardizzoni A. Chemotherapy treatment in malignant pleural mesothelioma: a difficult history. J Thorac Dis. 2018;10(Suppl 2):S304\u2013s10.","journal-title":"J Thorac Dis"},{"issue":"8","key":"7662_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11864-017-0488-7","volume":"18","author":"MMJ Disselhorst","year":"2017","unstructured":"Disselhorst MMJ, Burgers SJA, Baas P. Optimal therapy of advanced stage mesothelioma. Curr Treat Option On. 2017;18(8):48.","journal-title":"Curr Treat Option On"},{"issue":"8","key":"7662_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Can. 2017;17(8):475\u201388.","journal-title":"Nat Rev Can"},{"issue":"5","key":"7662_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","volume":"18","author":"EW Alley","year":"2017","unstructured":"Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18(5):623\u201330.","journal-title":"Lancet Oncol"},{"issue":"12","key":"7662_CR11","first-page":"1423","volume":"70","author":"ST Orr","year":"1986","unstructured":"Orr ST, Aisner J. Performance status assessment among oncology patients: a review. Cancer Treatment Rep. 1986;70(12):1423\u20139.","journal-title":"Cancer Treatment Rep"},{"issue":"2","key":"7662_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.5301\/tj.5000418","volume":"102","author":"R Berardi","year":"2016","unstructured":"Berardi R, Fiordoliva I, De Lisa M, Ballatore Z, Caramanti M, Morgese F, et al. Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma. Tumori. 2016;102(2):190\u20135.","journal-title":"Tumori"},{"issue":"9","key":"7662_CR13","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1200\/JCO.2010.34.5074","volume":"30","author":"D Olmos","year":"2012","unstructured":"Olmos D, A'Hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, et al. Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. J Clin Oncol. 2012;30(9):996\u20131004.","journal-title":"J Clin Oncol"},{"issue":"14","key":"7662_CR14","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344.","journal-title":"J Clin Oncol"},{"issue":"6","key":"7662_CR15","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.hoc.2005.09.010","volume":"19","author":"LM Krug","year":"2005","unstructured":"Krug LM. An overview of chemotherapy for mesothelioma. Hematol Oncol Clin North Am. 2005;19(6):1117\u201336 vii.","journal-title":"Hematol Oncol Clin North Am"}],"updated-by":[{"DOI":"10.1186\/s12885-021-07999-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07662-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-07662-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07662-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T04:06:38Z","timestamp":1615176398000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07662-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7662"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07662-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-33715\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-33715\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-33715\/v2","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"4 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12885-021-07999-y","URL":"https:\/\/doi.org\/10.1186\/s12885-021-07999-y","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval was obtained from the local research and audit committee (Royal Marsden Hospital).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DC Collins: Advisory board for Seattle genetics, GenMab, Merck, AZD. Honoraria from Genmab, Pfizer, Roche, Eli Lilly, AZD. Travel funding from Roche, AZD, BMS, Genmab. These are outside the submitted work.R Sundar: Advisory board for BMS, Merck, Eisai, Bayer, Taiho. Honoraria for talks from MSD, Eli Lilly, BMS, Roche, Taiho. Travel funding from Roche, Astra Zeneca, Taiho, Eisai. Research funding from Paxman Coolers, MSD. These are outside the submitted work.A Constantinidou: None declared.D Dolling: None declared.TA Yap: Research support from AstraZeneca, Bayer, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius\/Formation Biologics, F-Star, GlaxoSmithKline, Genentech, ImmuneSensor, Ipsen, Jounce, Karyopharm, Kyowa, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Sanofi, Seattle Genetics, Tesaro, and Vertex Pharmaceuticals. Consultancies with Almac, Aduro, AstraZeneca, Atrin, Axiom, Bayer, Calithera, Clovis, Cybrexa, EMD Serono, F-Star, Guidepoint, Ignyta, I-Mab, Jansen, Kyn Therapeutics, Merck, Pfizer, Roche, Seattle Genetics, and Zai Labs. These are outside the submitted work.S Popat: Honoraria from BMS, Roche, Takeda, AstraZeneca, Pfizer, MSD, EMD Serono, Guardant Health, AbbVie, Boehringer Ingelheim, Medscape, Tesaro, Paradox, Incyte, OncLive. Direct funding from Elsevier. These are outside the submitted work.MER O\u2019Brien: Advisory boards for MSD, Abbvie, BMS, BI, Pierre Fabre. These are outside the submitted work.U Banerji: Is a recipient of an NIHR Research Professorship Award and has received CRUK funding: Cancer Research UK Scientific Executive Board, Cancer Research UK Centre Award. Cancer Research UK Drug Discovery Committee \u2013 Programme Award. These are outside the submitted work.J de Bono: Has served on advisory boards and received fees from many companies including Astra Zeneca, Astellas, Bayer, Boehringer Ingelheim, Cellcentric, Daiichi, Genentech\/Roche, Genmab, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Menarini\/Silicon Biosystems, Orion, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Vertex Pharmaceuticals. He is an employee of The ICR, which have received funding or other support for his research work from AZ, Astellas, Bayer, Cellcentric, Daiichi, Genentech, Genmab, GSK, Janssen, Merck Serono, MSD, Menarini\/Silicon Biosystems, Orion, Sanofi Aventis, Sierra Oncology, Taiho, , Pfizer, Vertex, and which has a commercial interest in abiraterone, PARP inhibition in DNA repair defective cancers and PI3K\/AKT pathway inhibitors (no personal income). He was named as an inventor, with no financial interest, for patent 8,822,438. He has been the CI\/PI of many industry sponsored clinical trials. JDB is a National Institute for Health Research (NIHR) Senior Investigator. These are outside the submitted work.J Lopez: Research grant funding from Roche, Basilea, and Genmab. These are outside the submitted work.N Tunariu: None declared.A Minchom: Has served on advisory boards and received fees from Merck, Faron, Novartis, Bayer, Janssen. These are outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1210"}}